Tweet
MSD Animal Health has announced significant, global real-world data that support and reinforce the benefits of BRAVECTO® (fluralaner), the only flea and tick spot-on or chewable tablet that provides up to 12 weeks of protection for dogs. Six comprehensive studies recently published in peer-reviewed veterinary journals and one soon-to-be-published study support the benefits of longer-lasting flea and tick protection. The data evaluated the positive impact of extended duration flea and tick control in the U.K., U.S., Australia, Spain and South Africa, and measured the increase in adherence to veterinary recommendations that accompanies the extended duration of action.
Nicola Barclay, Senior Product Manager at MSD Animal Health comments: “These studies show that, by using a longer-acting flea and tick product, dog owners are more likely to keep their dogs protected from fleas and ticks for more months of the year, and are more likely to follow their veterinarian’s recommendation of using flea and tick product year-round. Furthermore, when compared to monthly flea and tick products, dog owners preferred BRAVECTO and reported the convenience of less-frequent dosing as a key benefit of extended duration flea and tick control.”
Dogs owners using longer-lasting BRAVECTO adhered better to veterinarian flea and tick treatment recommendations, providing their dogs with more months of protection. In flea and tick control, pet owner adherence to treatment recommendations is critical for medication effectiveness, and lack of adherence is thought to be a common cause of treatment failure.
In a study of 25 veterinary practices in the U.S. from April to June 2016, 559 dog owners completed a survey about their experience with BRAVECTO and monthly flea and tick medications. The results of the survey found that nearly 90 percent of dog owners (89%) preferred BRAVECTO vs. monthly medications. Respondents identified convenience (74%), the 12-week dosing interval (69%), and less-frequent dosing (68%) as the three most important benefits of using BRAVECTO. An additional two surveys were conducted to evaluate the responses of dog owners in the UK and Australia regarding their flea and tick treatment preferences and to compare the results across the three countries; the results of which are soon-to-be-published. In the analysis of responses from 1,608 dog owners across the three countries, preference for BRAVECTO vs. monthly medications was uniformly high (89% U.S., 92% UK, 82% Australia). Dog owners also reported high satisfaction (93-96%) with the extended duration flea and tick product. Furthermore, most participating dog owners thought that they were more likely to give the follow-up doses on time for fluralaner compared to monthly products (65% U.S., 74% UK, 63% Australia).
Fleas and ticks are not just a nuisance, but also pose animal and human health risks, as they can transmit the pathogens responsible for diseases such as Lyme disease, Babesiosis and Bartonellosis. For more information on disease risks from parasites please visit www.bigfleaproject.co.uk.